Suppr超能文献

去泛素化酶 UCH-L1 是一种致癌基因,通过调节 PHLPP1 和 Akt 信号通路来驱动体内淋巴瘤的发展。

The de-ubiquitinase UCH-L1 is an oncogene that drives the development of lymphoma in vivo by deregulating PHLPP1 and Akt signaling.

机构信息

Department of Pediatrics and Adolescent Medicine, Mayo Clinic, Rochester, MN 55906, USA.

出版信息

Leukemia. 2010 Sep;24(9):1641-55. doi: 10.1038/leu.2010.138. Epub 2010 Jun 24.

Abstract

De-ubiquitinating enzymes (DUBs) can reverse the modifications catalyzed by ubiquitin ligases and as such are believed to be important regulators of a variety of cellular processes. Several members of this protein family have been associated with human cancers; however, there is little evidence for a direct link between deregulated de-ubiquitination and neoplastic transformation. Ubiquitin C-terminal hydrolase (UCH)-L1 is a DUB of unknown function that is overexpressed in several human cancers, but whether it has oncogenic properties has not been established. To address this issue, we generated mice that overexpress UCH-L1 under the control of a ubiquitous promoter. Here, we show that UCH-L1 transgenic mice are prone to malignancy, primarily lymphomas and lung tumors. Furthermore, UCH-L1 overexpression strongly accelerated lymphomagenesis in Emu-myc transgenic mice. Aberrantly expressed UCH-L1 boosts signaling through the Akt pathway by downregulating the antagonistic phosphatase PHLPP1, an event that requires its de-ubiquitinase activity. These data provide the first in vivo evidence for DUB-driven oncogenesis and suggest that UCH-L1 hyperactivity deregulates normal Akt signaling.

摘要

去泛素化酶(DUBs)可以逆转泛素连接酶催化的修饰,因此被认为是多种细胞过程的重要调节剂。该蛋白家族的几个成员与人类癌症有关;然而,在去泛素化的失调与肿瘤转化之间缺乏直接联系的证据。泛素 C 端水解酶(UCH)-L1 是一种功能未知的 DUB,在几种人类癌症中过度表达,但它是否具有致癌特性尚未确定。为了解决这个问题,我们生成了在广泛启动子控制下过表达 UCH-L1 的小鼠。在这里,我们表明 UCH-L1 转基因小鼠易发生恶性肿瘤,主要是淋巴瘤和肺肿瘤。此外,UCH-L1 的过表达强烈加速了 Emu-myc 转基因小鼠的淋巴瘤发生。异常表达的 UCH-L1 通过下调拮抗磷酸酶 PHLPP1 来增强 Akt 途径的信号,这一事件需要其去泛素酶活性。这些数据为 DUB 驱动的致癌作用提供了第一个体内证据,并表明 UCH-L1 的过度活跃会使正常的 Akt 信号失调。

相似文献

2
UCH-L1 promotes invasion of breast cancer cells through activating Akt signaling pathway.
J Cell Biochem. 2018 Jan;119(1):691-700. doi: 10.1002/jcb.26232. Epub 2017 Jul 31.
4
Ubiquitin hydrolase UCH-L1 destabilizes mTOR complex 1 by antagonizing DDB1-CUL4-mediated ubiquitination of raptor.
Mol Cell Biol. 2013 Mar;33(6):1188-97. doi: 10.1128/MCB.01389-12. Epub 2013 Jan 7.
5
PU.1-dependent regulation of UCH L1 expression in B-lymphoma cells.
Leuk Lymphoma. 2011 Jul;52(7):1336-47. doi: 10.3109/10428194.2011.562571. Epub 2011 Apr 20.
6
UCH-L1 is induced in germinal center B cells and identifies patients with aggressive germinal center diffuse large B-cell lymphoma.
Blood. 2016 Mar 24;127(12):1564-74. doi: 10.1182/blood-2015-07-656678. Epub 2015 Dec 23.
7
Ubiquitin C-terminal hydrolase-L1 is a key regulator of tumor cell invasion and metastasis.
Oncogene. 2009 Jan 8;28(1):117-27. doi: 10.1038/onc.2008.364. Epub 2008 Sep 29.
8
UCH-L1 bypasses mTOR to promote protein biosynthesis and is required for MYC-driven lymphomagenesis in mice.
Blood. 2018 Dec 13;132(24):2564-2574. doi: 10.1182/blood-2018-05-848515. Epub 2018 Sep 26.

引用本文的文献

3
Identification of PANoptosis-based signature for predicting the prognosis and immunotherapy response in AML.
Heliyon. 2024 Nov 8;10(22):e40267. doi: 10.1016/j.heliyon.2024.e40267. eCollection 2024 Nov 30.
4
UCHL1 Overexpression Is Related to the Aggressive Phenotype of Non-small Cell Lung Cancer.
Tuberc Respir Dis (Seoul). 2024 Oct;87(4):494-504. doi: 10.4046/trd.2023.0166. Epub 2024 Aug 16.
6
Proteomic profiling of prostate cancer reveals molecular signatures under antiandrogen treatment.
Clin Proteomics. 2024 Jun 26;21(1):44. doi: 10.1186/s12014-024-09490-9.
7
UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas.
Cell Rep Med. 2024 Feb 20;5(2):101381. doi: 10.1016/j.xcrm.2023.101381. Epub 2024 Jan 19.
8
UCHL1 Regulates Radiation Lung Injury via Sphingosine Kinase-1.
Cells. 2023 Oct 5;12(19):2405. doi: 10.3390/cells12192405.
10
Ubiquitin C‑terminal hydrolase‑L1: A new cancer marker and therapeutic target with dual effects (Review).
Oncol Lett. 2023 Feb 8;25(3):123. doi: 10.3892/ol.2023.13709. eCollection 2023 Mar.

本文引用的文献

1
The ubiquitin C-terminal hydrolase UCH-L1 regulates B-cell proliferation and integrin activation.
J Cell Mol Med. 2009 Aug;13(8B):1666-1678. doi: 10.1111/j.1582-4934.2008.00501.x.
3
beta-TrCP-mediated ubiquitination and degradation of PHLPP1 are negatively regulated by Akt.
Mol Cell Biol. 2009 Dec;29(23):6192-205. doi: 10.1128/MCB.00681-09. Epub 2009 Sep 21.
4
TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas.
Blood. 2009 Sep 17;114(12):2467-75. doi: 10.1182/blood-2008-12-194852. Epub 2009 Jul 16.
6
Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma.
Nature. 2009 Jun 4;459(7247):717-21. doi: 10.1038/nature07968. Epub 2009 May 3.
7
Frequent inactivation of A20 in B-cell lymphomas.
Nature. 2009 Jun 4;459(7247):712-6. doi: 10.1038/nature07969. Epub 2009 May 3.
8
TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma.
J Exp Med. 2009 May 11;206(5):981-9. doi: 10.1084/jem.20090528. Epub 2009 Apr 20.
9
Principles of cancer therapy: oncogene and non-oncogene addiction.
Cell. 2009 Mar 6;136(5):823-37. doi: 10.1016/j.cell.2009.02.024.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验